We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

Fund managers haven’t disclosed any holdings of BTAI yet.

BTAI Hedge Fund Activity: Q1 2026 in Review

40 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q1 2026, worth a combined $7.28M — up 28% from $5.66M a quarter earlier.

Fund positioning in BTAI was balanced in Q1 2026: 8 funds opened new positions, 8 closed out, 9 added to existing stakes and 7 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $3.15M. The largest seller was Jane Street, exiting entirely with an estimated $204K sold.

  • 40 institutional investors held BioXcel Therapeutics (BTAI) as of Q1 2026, down from 41 in Q4 2025.
  • Funds reported $7.28M of BioXcel Therapeutics stock for Q1 2026, up 28% quarter-over-quarter.
  • 8 funds opened new BioXcel Therapeutics positions in Q1 2026 and 8 closed out, a net change of 0 holders.
  • The largest BioXcel Therapeutics buyer in Q1 2026 was Armistice Capital, an estimated $3.15M added.
  • The largest BioXcel Therapeutics seller in Q1 2026 was Jane Street, an estimated $204K sold.

Based on aggregated 13F filings for Q1 2026.